NLS Intellectual Property

The European Patent Office (EPO) has granted a further patent in Salipro Biotech’s patent portfolio: European Patent entitled “Production of Salipro particles”. This patent covers processes related to the Salipro platform and represents a pivotal milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, […]

AlzeCure Pharma has announced that the patent offices in China, India, South Africa, Israel, Hong Kong and Mexico have granted patents covering the company’s clinical drug candidate ACD856, which is being developed against Alzheimer’s and other disorders with cognitive impairment. “This further strengthens the patent portfolio for ACD856 and is an important part of our […]

NEOGAP Therapeutics has been granted a patent in Australia for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent strengthens NEOGAP’s strategic intellectual property portfolio and marks an important step in the company’s efforts to develop groundbreaking treatments for autoimmune diseases such as MS, it states. […]

The United States Patent and Trademark Office (USPTO) has issued US Patent covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer. The patent, titled ”Novel peptides”, provides ATOR-4066 with protection regarding methods of treating cancer and/or a tumor using a bispecific antibody comprising the complementarity-determining regions (CDRs) […]

Capitainer has announced the grant of three US patents for their soon to be launched plasma/serum separation device. “These patents reinforce our strategic position, facilitating Capitainer’s expansion in the US market. The recognition from the United States Patent Office is a testament to the technological advancements we’ve achieved. This enables us to extend our advanced […]

Elicera Therapeutics has received a Notice of Allowance from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies. Once granted, the patent can be kept in force until 2036. “iTANK is one of our key assets and together with the recently approved European patent we now […]